INVENTIVA - (EGFF)

Inventiva is a late-stage clinical-stage biopharmaceutical company. The promoter is a French biotechnology company with an in-depth expertise in small molecules targeting nuclear receptors, transcription factors and epigenetic enzymes. The company has built a strong pipeline of drug candidate for the treatment of patients with fibrosis, lysosomal storage disorders and cancers. The project supports the company's research and development (R&D) investments, including the clinical regulatory and manufacturing development costs of all portfolio candidates, with a focus on the lead products (e.g. Lanifibranor). Investments will cover predominantly R&D costs to bring the assets closer to the market authorisation and commercialisation.

The aim is to support the development of treatments of NASH (non-alcoholic steatohepatitis) and other fibrotic diseases, as well as treatments for other conditions, such as lysosomal storage disorder and various cancers. Additionally, the EIB loan will also contribute to accelerate the screening and early stage pre-clinical development of new products, which are expected to become the backbone of the company's growth. The project will be coordinated from the company's headquarters located in Daix near Dijon (France).

The promoter's investments concern research, development and innovation activities that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2014/52/EU (amending 2011/92/EU). Full environmental details verified during appraisal.

The promoter is a public company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by EU directives on procurement. However, the promoter's procurement procedures are expected to be in line with the EIB guidelines for private sector projects. The EIB's services verified details during the project due diligence.